肺纤维化合并肺气肿的死亡替代指标
在两项IPF队列中,CT视觉肺气肿>0%定义CPFE,并按10%或15%阈值及无监督机器学习分组。≥10%肺气肿者1年DLCO下降与死亡关联强于FVC下降;非CPFE者1年FVC下降≥5%和≥10%与死亡强关联。
要点
- ≥10%肺气肿的CPFE患者应关注1年DLCO下降而非FVC下降。
- 非CPFE的IPF患者1年FVC下降≥5%和≥10%与死亡强关联。
- 无监督机器学习可识别FVC下降与死亡关联不强的CPFE亚组。
核心结论
- 评估IPF疾病进展时,≥10%肺气肿患者应考虑DLCO下降,非CPFE患者应考虑1年相对FVC下降≥5%阈值。
研究设计与样本
- 两项IPF队列研究:衍生队列CPFE/non-CPFE为317/183例,重复队列为358/152例。
- CT视觉肺气肿>0%定义CPFE,并按10%或15%阈值及无监督机器学习模型分组。
- 采用线性混合效应模型分析1年相对FVC和DLCO下降,多变量Cox回归分析死亡关联。
主要发现
- 在两个IPF队列中,≥10%肺气肿的CPFE患者较<10%肺气肿者吸烟史更多且基线DLCO更低。
- 在≥10%肺气肿患者中,1年DLCO下降与死亡的关联强于1年FVC下降。
- 结果在适合IPF治疗试验的患者、≥15%肺气肿亚组及无监督机器学习分组中保持一致。
- 无监督机器学习识别出FVC下降与死亡关联不强的CPFE患者。
- 在非CPFE的IPF患者中,1年FVC下降≥5%和≥10%与死亡强关联。
临床怎么用
- 对≥10%肺气肿的CPFE患者,随访疾病进展时应重视DLCO下降。
- 对非CPFE的IPF患者,可考虑以1年相对FVC下降≥5%作为进展评估阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) with coexistent emphysema, termed combined pulmonary fibrosis and emphysema (CPFE) may associate with reduced forced vital capacity (FVC) declines compared to non-CPFE IPF patients. We examined associations between mortality and functional measures of disease progression in two IPF cohorts. METHODS: Visual emphysema presence (>0% emphysema) scored on computed tomography identified CPFE patients (CPFE/non-CPFE: derivation cohort n=317/n=183, replication cohort n=358/n=152), who were subgrouped using 10% or 15% visual emphysema thresholds, and an unsupervised machine-learning model considering emphysema and interstitial lung disease extents. Baseline characteristics, 1-year relative FVC and diffusing capacity of the lung for carbon monoxide (D LCO) decline (linear mixed-effects models), and their associations with mortality (multivariable Cox regression models) were compared across non-CPFE and CPFE subgroups. RESULTS: In both IPF cohorts, CPFE patients with ≥10% emphysema had a greater smoking history and lower baseline D LCO compared to CPFE patients with <10% emphysema. Using multivariable Cox regression analyses in patients with ≥10% emphysema, 1-year D LCO decline showed stronger mortality associations than 1-year FVC decline. Results were maintained in patients suitable for therapeutic IPF trials and in subjects subgrouped by ≥15% emphysema and using unsupervised machine learning. Importantly, the unsupervised machine-learning approach identified CPFE patients in whom FVC decline did not associate strongly with mortality. In non-CPFE IPF patients, 1-year FVC declines ≥5% and ≥10% showed strong mortality associations. CONCLUSION: When assessing disease progression in IPF, D LCO decline should be considered in patients with ≥10% emphysema and a ≥5% 1-year relative FVC decline threshold considered in non-CPFE IPF patients.
引用
- Zhao A, Gudmundsson E, Mogulkoc N, et al. Mortality surrogates in combined pulmonary fibrosis and emphysema. Eur Respir J. 2024. PMID: 37973176. doi:10.1183/13993003.00127-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。